Brown Brothers Harriman & Co. Has $51.41 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Brown Brothers Harriman & Co. reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 355,495 shares of the company's stock after selling 9,140 shares during the quarter. Brown Brothers Harriman & Co.'s holdings in Johnson & Johnson were worth $51,412,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. IFS Advisors LLC boosted its holdings in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after acquiring an additional 100 shares during the period. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $29,000. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at $32,000. Runnymede Capital Advisors Inc. bought a new position in Johnson & Johnson during the 4th quarter worth $38,000. Finally, NewSquare Capital LLC lifted its holdings in shares of Johnson & Johnson by 145.8% during the fourth quarter. NewSquare Capital LLC now owns 290 shares of the company's stock worth $42,000 after buying an additional 172 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 1.5 %

NYSE JNJ traded up $2.47 on Monday, hitting $166.18. The company's stock had a trading volume of 5,793,396 shares, compared to its average volume of 9,037,503. The firm has a market cap of $400.48 billion, a PE ratio of 24.99, a PEG ratio of 2.56 and a beta of 0.47. The company's 50-day moving average is $158.68 and its 200 day moving average is $156.07. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Remove Ads

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.29 EPS. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 2.98%. Johnson & Johnson's payout ratio is 74.59%.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Bank of America raised their price target on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a "neutral" rating in a research report on Wednesday, March 5th. Wells Fargo & Company reduced their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Stifel Nicolaus dropped their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research report on Thursday, January 23rd. Citigroup reduced their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Finally, Morgan Stanley cut their target price on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $171.33.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.